If there’s anything last year’s Qantas data breach has taught us, it’s that your online information isn’t as secure as you think it is. While you may think you’ve secure ...

The Melonga App guides users through a number of therapeutic techniques, tips and exercises designed by urologists and ...

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced the appointment of Thomas Fagan as Executive Vice ...

Measured in blood samples, the biomarker p-tau217 was strongly linked to future dementia risk across decades of follow-up in a large, diverse cohort of U.S. women ...

The literature and research consistently affirm that self-motivation drives academic, educational, and personal potential.

Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge company is on its ...

Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease ...

Cognito Therapeutics, a company using visual and auditory stimulation to treat neurodegenerative disorders, announced it closed an oversubscribed $105 million Series C funding round. Morningside ...

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced the final close of its ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted 2027 U.S. market entry. Spectris delivers coordinated visual and auditory ...